{"nct_id":"NCT04649359","title":"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2021-02-02","start_date_type":"ACTUAL","primary_completion_date":"2022-06-17","primary_completion_date_type":"ACTUAL","completion_date":"2026-12-31","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["PFE"]}